{"id":"3-4-diaminopyridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Paresthesia"},{"rate":null,"effect":"Seizures"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"3,4-diaminopyridine is a potassium channel blocker that enhances neuromuscular transmission by prolonging the presynaptic action potential, thereby increasing the influx of calcium and the release of acetylcholine. This mechanism is particularly beneficial in conditions characterized by impaired neuromuscular transmission, such as Lambert-Eaton myasthenic syndrome (LEMS), where there is a deficiency in acetylcholine release.","oneSentence":"3,4-diaminopyridine blocks potassium channels to prolong action potential duration and increase acetylcholine release at the neuromuscular junction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:57:01.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lambert-Eaton myasthenic syndrome (LEMS)"}]},"trialDetails":[{"nctId":"NCT02189720","phase":"","title":"Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome","status":"APPROVED_FOR_MARKETING","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"","conditions":"Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired","enrollment":""},{"nctId":"NCT03579966","phase":"PHASE3","title":"Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)","status":"TERMINATED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2018-06-11","conditions":"Myasthenia Gravis, MuSK, AChR Myasthenia Gravis","enrollment":63},{"nctId":"NCT01825395","phase":"","title":"Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome","status":"APPROVED_FOR_MARKETING","sponsor":"University of Colorado, Denver","startDate":"","conditions":"Lambert Eaton Myasthenic Syndrome","enrollment":""},{"nctId":"NCT03781479","phase":"PHASE2","title":"Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients","status":"COMPLETED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2019-01-21","conditions":"Muscular Atrophy, Spinal","enrollment":13},{"nctId":"NCT02562066","phase":"PHASE3","title":"Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes","status":"COMPLETED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2016-01","conditions":"Myasthenic Syndromes, Congenital","enrollment":20},{"nctId":"NCT00704925","phase":"","title":"Treatment of Lambert-Eaton Syndrome With 3,4 DAP","status":"NO_LONGER_AVAILABLE","sponsor":"David P. Richman, MD","startDate":"","conditions":"Lambert Eaton Myasthenic Syndrome","enrollment":""},{"nctId":"NCT02090725","phase":"PHASE2","title":"Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)","status":"TERMINATED","sponsor":"Jeffrey A. Cohen, MD","startDate":"2004-02","conditions":"Muscle Weakness","enrollment":4},{"nctId":"NCT01377922","phase":"PHASE3","title":"A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)","status":"COMPLETED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2011-06","conditions":"Lambert Eaton Myasthenic Syndrome","enrollment":38},{"nctId":"NCT01511978","phase":"PHASE2","title":"Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome","status":"COMPLETED","sponsor":"Jacobus Pharmaceutical","startDate":"2012-01","conditions":"Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome","enrollment":32},{"nctId":"NCT01378546","phase":"","title":"Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP","status":"NO_LONGER_AVAILABLE","sponsor":"Louis H. Weimer, MD","startDate":"2005-05","conditions":"Lambert Eaton Myasthenic Syndrome (LEMS)","enrollment":""},{"nctId":"NCT00342381","phase":"PHASE2","title":"Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2006-06","conditions":"Multiple Sclerosis, Fatigue","enrollment":120}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"CONDITION AGGRAVATED"},{"count":3,"reaction":"COUGH"},{"count":3,"reaction":"CYANOSIS"},{"count":3,"reaction":"DEPRESSED LEVEL OF CONSCIOUSNESS"},{"count":3,"reaction":"DROOLING"},{"count":3,"reaction":"DYSPNOEA"},{"count":3,"reaction":"HYPOTONIA"},{"count":3,"reaction":"INCREASED BRONCHIAL SECRETION"},{"count":3,"reaction":"RESPIRATORY DEPRESSION"},{"count":2,"reaction":"ASTHENIA"}],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["3,4DAP","3,4-DAP","3,4 DAP","DAP"],"phase":"phase_3","status":"active","brandName":"3,4-diaminopyridine","genericName":"3,4-diaminopyridine","companyName":"Oregon Health and Science University","companyId":"oregon-health-and-science-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"3,4-diaminopyridine blocks potassium channels to prolong action potential duration and increase acetylcholine release at the neuromuscular junction. Used for Lambert-Eaton myasthenic syndrome (LEMS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}